The recently reported COH34 is a novel small‐molecule PARG inhibitor with nanomolar potency both in vitro and in vivo, and notably, with efficiently killing effect on PARP inhibitor‐resistant cancer cells, which makes it a good candidate for clinical studies.169. This evidence concerns the gene PARP1 and cancer.